These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7479739)

  • 21. An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response.
    Hu XD; Chen ST; Li JY; Yu DH; Yi-Zhang ; Cai H
    Vaccine; 2010 Mar; 28(12):2408-15. PubMed ID: 20064480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
    Koido S; Tanaka Y; Chen D; Kufe D; Gong J
    J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral.
    Apostolopoulos V; Osinski C; McKenzie IF
    Nat Med; 1998 Mar; 4(3):315-20. PubMed ID: 9500605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
    Karanikas V; Hwang LA; Pearson J; Ong CS; Apostolopoulos V; Vaughan H; Xing PX; Jamieson G; Pietersz G; Tait B; Broadbent R; Thynne G; McKenzie IF
    J Clin Invest; 1997 Dec; 100(11):2783-92. PubMed ID: 9389743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Kerkvliet NI; Baecher-Steppan L; Shepherd DM; Oughton JA; Vorderstrasse BA; DeKrey GK
    J Immunol; 1996 Sep; 157(6):2310-9. PubMed ID: 8805628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses.
    McKenzie IF; Apostolopoulos V; Lees C; Xing PX; Lofthouse S; Osinski C; Popovski V; Acres B; Pietersz G
    Vet Immunol Immunopathol; 1998 May; 63(1-2):185-90. PubMed ID: 9656453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway.
    Apostolopoulos V; Pietersz GA; Gordon S; Martinez-Pomares L; McKenzie IF
    Eur J Immunol; 2000 Jun; 30(6):1714-23. PubMed ID: 10898509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human interleukin-12 enhances interferon-gamma-producing influenza-specific memory CD8+ cytotoxic T lymphocytes.
    Mbawuike IN; Fujihashi K; DiFabio S; Kawabata S; McGhee JR; Couch RB; Kiyono H
    J Infect Dis; 1999 Nov; 180(5):1477-86. PubMed ID: 10515806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer.
    Wu WC; Jin DY; Lou WH; Wang DS; Qin XY
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1861-8. PubMed ID: 20229033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmid DNA vaccines are effective in the absence of IFNgamma.
    Hassett DE; Zhang J; Whitton JL
    Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential development of CD4 and CD8 cytotoxic T cells (CTL) in PBMC across the leprosy spectrum; IL-6 with IFN-gamma or IL-2 generate CTL in multibacillary patients.
    de la Barrera S; Finiasz DM; Fink S; Valdez R; Bottasso O; Balina LM; Sasiain MC
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):45-55. PubMed ID: 9207753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF.
    Chu Y; Xia M; Lin Y; Li A; Wang Y; Liu R; Xiong S
    Cancer Gene Ther; 2006 May; 13(5):510-9. PubMed ID: 16341143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.
    Samuel J; Budzynski WA; Reddish MA; Ding L; Zimmermann GL; Krantz MJ; Koganty RR; Longenecker BM
    Int J Cancer; 1998 Jan; 75(2):295-302. PubMed ID: 9462722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
    Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
    J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses.
    Tang CK; Sheng KC; Pouniotis D; Esparon S; Son HY; Kim CW; Pietersz GA; Apostolopoulos V
    Vaccine; 2008 Jul; 26(31):3827-34. PubMed ID: 18550230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
    Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
    J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.